PPARG and polycystic ovary syndrome: PPARγ agonist, thiazolidinedione (TZD, including troglitazone, rosiglitazone and pigolitazone), is currently used to treat type diabetes (NIDDM) and also to attenuate the secondary clinical symptoms frequently associated with insulin resistance including polycystic ovary syndrome (PCOS) [1-4].